Phase 2 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For the patient receiving the transplant:
- You have been diagnosed with a specific blood cancer (such as certain types of leukemia, lymphoma, myeloma, or related conditions) that has been confirmed by lab testing and meets specific stage or treatment history requirements (confirm with trial site for your exact diagnosis)
- You are age 50 or older, OR you are between 18 and 49 years old AND at least one of the following applies: you have had a previous stem cell transplant, you have taken certain antibody-based cancer drugs before, you have significant health conditions alongside your cancer, your general health/ability to function is somewhat reduced, or your doctor considers standard high-intensity transplant preparation too risky for you
- You have at least one suitable donor available — either a partially matched family member or a fully matched related or unrelated donor
- Your general health and ability to function day-to-day meets a minimum standard (a score of 70 or higher on a standard health scale)
- Your heart is pumping well enough (at least 45% efficiency on an ultrasound test)
- Your lungs are working well enough (at least 50% of expected function on breathing tests)
- Your kidneys are filtering blood well enough (a minimum level on a standard kidney function calculation)
- Your liver test results are within acceptable ranges
- You agree to use highly effective birth control for at least one year after the transplant if there is any chance you could become pregnant or father a child
- If you could become pregnant, you must have a negative pregnancy test within 7 days before starting the treatment preparation
- You are willing and able to understand and sign a consent form
For the stem cell donor:
- If the donor is a family member, they must be at least 12 years old; if they are an unrelated donor, they must be at least 18 years old
- The donor has been assessed and approved as eligible to donate according to the relevant medical institution's standards
- The donor (or their parent/legal guardian) is willing and able to sign a consent form
Who may not be able to join:
For the patient receiving the transplant:
- You are currently taking part in another clinical trial using an experimental treatment, or you have taken an experimental treatment within the last 2 weeks
- You are currently breastfeeding
- You have another type of cancer (not a blood cancer, and not a common skin cancer) that has spread to other parts of the body, has come back or is not responding to treatment, cannot be cured, or was treated with the aim of cure within the last 2 years
- You have had a serious allergic reaction to medicines that are similar to those used in this trial
- You have another serious, uncontrolled health condition (such as a severe hormone disorder, serious blood clotting problem, major chemical imbalance in your body, active hepatitis infection, or uncontrolled dental infection) that your doctor believes would make a transplant unsafe for you
For the stem cell donor:
- No specific reasons to exclude a donor have been listed in the trial criteria
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Christopher G Kanakry, M.D., National Cancer Institute (NCI)
Phone: (240) 858-3755
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Phase II: Evaluate the efficacy of PTCy, at the lowest dose determined for each HLA-matching arm from phase I, as assessed by 1-year GVHD-free relapse-free survival (GRFS) rate.; Phase I: Determine the lowest effective dose of PTCy in combination with sirolimus and mycophenolate mofetil as GVHD prophylaxis after reduced intensity conditioning and PBSCT, as assessed by primary graft failure AND Grade III-IV acute GVHD as ...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.